The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 91)
Research Grant, 2018
Leucine-rich repeat kinase 2 (LRRK2) is the greatest known genetic contributor to Parkinson's disease (PD). One important function of LRRK2 is to modify itself and proteins called Rab GTPases in a process known as a kinase activity. Parkinson's-linked mutations (changes) in the LRRK2 gene enhance the kinase activity of this protein, making this activity a possible therapeutic targe...
Researchers: Adamantios Mamais, PhD
LRRK2 Biology Consortium, 2017
Development of Nanobodies as Novel Tools to Characterize LRRK2 as a Potential Drug Target for Parkinson's Disease
Several genes play a crucial role in Parkinson's disease (PD). The most common genetic cause of PD is mutations in the gene encoding LRRK2, a very large and complex protein with different enzyme (accelerates chemical reactions) functions. Targeting the multiple enzymatic functions of LRRK2 represents a very attractive approach for designing novel therapeutics for PD that requires ...
Research Grant, 2017
A reliable, characterized and validated model of synucleinopathies (disorders in which there is an excessive accumulation of the protein alpha-synuclein) would provide a critical tool with which to study the pathophysiology of Parkinson's disease (PD) and test potential neuroprotective therapies. Synucleinopathy induced in neurons by sonicated (applying sound waves) preformed alph...
Researchers: Caryl E. Sortwell, PhD
Oligomeric & pS129 Assay LEAPS, 2017
Exploring the Use of Alpha-synuclein Assays for Translational Biomarkers and Pharmaceutical Intervention Trials
Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. The biggest roadblock facing the development of disease-modifying therapies is the lack of reliable biomarkers (trackers of disease activity), which affects the reliability of clinical trials. Thus, the development of a simple diagnostic test to aid in the clinical diagnosis of ...
Researchers: Omar El-Agnaf, PhD
Target Advancement Program, 2017
Homeostasis (balance) of mitochondria, the powerhouses of cells, is crucial for longevity. Accumulation of damaged mitochondria is toxic for cells, which is believed to be one of the triggers that leads to neurodegeneration in Parkinson's disease (PD). We plan to investigate the cellular mechanisms of a mitochondrial safeguard, the protein kinase (enzyme that modifies proteins) PIN...
Researchers: Marius K. Lemberg, Dr Sc